English
Cohance Lifesciences Q3 Results
- BSE: 543064
- NSE: COHANCE
- ISIN: INE03QK01018
- Sector: Biotechnology & Drugs
BSE
535.00
3.80 (0.72%)
3.80 (0.72%)Volume19.27 K
Updated: Fri 12 Dec, 2025 | 15:29:04
NSE
536.005.30 (1.00%)
5.30 (1.00%)Volume5.15 L
Updated: Fri 12 Dec, 2025 | 15:29:57
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - Cohance Lifesciences Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 24 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 209.80 | 436.19 | -51.90% | 167.43 | 25.31% |
| Depreciation/ Amortization | 20.35 | 37.79 | -46.15% | 12.75 | 59.59% |
| Operating Income | 97.35 | 167.58 | -41.91% | 52.39 | 85.81% |
| Net Income | 82.88 | 138.47 | -40.15% | 46.75 | 77.27% |
| Other Operating Expenses Total | 70.53 | 122.86 | -42.59% | 14.42 | 389.16% |
| Net Income Before Taxes | 109.73 | 174.16 | -36.99% | 65.47 | 67.61% |
| Total Revenue | 307.15 | 603.77 | -49.13% | 219.82 | 39.73% |
| Selling/ General/ Admin Expenses Total | 63.29 | 102.07 | -37.99% | 32.83 | 92.77% |
| Diluted Normalized EPS | 3.23 | 3.61 | -10.53% | 1.84 | 75.54% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.